fbpx

SIGN IN YOUR ACCOUNT TO HAVE ACCESS TO DIFFERENT FEATURES

FORGOT YOUR PASSWORD?

FORGOT YOUR DETAILS?

AAH, WAIT, I REMEMBER NOW!
+1 786 238 2170

Global Stem Cells GroupGlobal Stem Cells Group

  • Home
  • Our Story
  • Advisory Board
  • Investors
  • Companies
  • Press Releases
  • Blog
CONTACT
  • Home
  • Press Releases
  • Bioheart, Inc. and Global Stem Cells, Inc. Announce New Clinical Site in Mexico
April 1, 2023

Bioheart, Inc. and Global Stem Cells, Inc. Announce New Clinical Site in Mexico

Wednesday, 06 November 2013 / Published in Press Releases

Bioheart, Inc. and Global Stem Cells, Inc. Announce New Clinical Site in Mexico

Bioheart, Inc., in collaboration with Global Stem Cells, Inc. have initiated a new clinical site in Cozumel, Mexico.
Bioheart Inc., a biotech company focused on the discovery, development and commercialization of autologous cell therapies, has announced that it has initiated a new clinical site in collaboration with Global Stem Cell Group, Inc. in Cozumel, Mexico. The two companies successfully treated their first congestive heart failure patient at the new clinical site last week, using Bioheart’s AdipoCell (adipose derived stem cells).
The therapy involved the use of stem cells derived from the patient’s own fat (adipose tissue) obtained using liposuction. The recovered stem cells were injected into the patients’ heart with Bioheart’s MyoCath® needle injection catheter which allows for introduction of the cells directly into the heart without invasive surgery.
Rafael Moguel, M.D., Head of the Cardiac Program at the Centro Medico de Cozumel, was the treating interventional cardiologist for the Bioheart therapy procedure.
“Our center is very excited to participate in the cutting edge programs at Bioheart,” Moguel says. “We can offer new hope to patients suffering from debilitating diseases by utilizing regenerative medicine, and delivering them non-invasively into the heart.”
The MyoCath catheter was introduced using a radial artery approach, the first such documented stem cell case using this delivery method. The benefit of a radial artery approach is that it does not require the patient to lie flat for up to six hours, as in a femoral artery approach. Patients are able to sit up, walk and eat immediately following the procedure, and the risk of internal bleeding is eliminated.
Bioheart and Global Stem Cells Group have designed several different protocols to be utilized at the center in Cozumel, offering treatments to patients for a variety of different indications.
About Bioheart, Inc.:
Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart’s goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient’s quality of life and reduce health care costs and hospitalizations.
Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient’s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com.

What you can read next

Stem Cell Training Inc. Announces Alliance with Far Eastern University to Advance in-Office Stem Cell Procedures
Stem Cell Training, Inc. Announces Joint Venture with The Research Center in Tissue Engineering and Cellular Therapy at Maimonides University
Global Stem Cells Group, Inc. Announces Plans to Attend 21st Annual World Congress on Anti-Aging, Regenerative and Aesthetic Medicine in Las Vegas, Dec. 15, 2013

Send Us a Message

  • Home
  • Our Story
  • Advisory Board
  • Investors
  • Companies
  • Testimonials
  • Press Releases
  • Blog

Copyright © 2022 Stem Cells Group | All Rights Reserved

CONTACT US

Datran Center 9100 S Dadeland Boulevard, Suite 1500. Miami Fl. 33156 United States

305-560-5337

info@stemcellsgroup.com

STAY CONNECTED

Get the latest news, updates, and promotions. Follow us on our social networks.

Certification issued by ISSCA and endorsed by the Marmara University, Universidad Autónoma del BENI: UAB and by the Atlantic International University

  • Home
  • Our Story
  • Advisory Board
  • Investors
  • Companies
  • Testimonials
  • Press Releases
  • Blog

Copyright © 2022 Stem Cells Group | All Rights Reserved

CONTACT US

Datran Center 9100 S Dadeland Boulevard, Suite 1500. Miami Fl. 33156 United States

305-560-5337

info@stemcellsgroup.com

STAY CONNECTED

Get the latest news, updates, and promotions. Follow us on our social networks.

Certification issued by ISSCA and endorsed by the Marmara University, Universidad Autónoma del BENI: UAB and by the Atlantic International University

TOP